ArticleNature medicine2023
Evolution of synchronous female bilateral breast cancers and response to treatment.
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- Expression of Estrogen Receptor Alpha and Ki-67 in Synchronous Canine Mammary Tumors.Journal of mammary gland biology and neoplasia · 2026Article
- Article
- Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives.Breast cancer (Dove Medical Press) · 2026Review
- Early Distant Metastasis in Synchronous Bilateral Breast Cancer including a Small Low-Grade Carcinoma with Osteoclast-Like Giant Cells: A Case Report.Surgical case reports · 2026Article
- Advanced Metastatic Bilateral Breast Carcinoma in a Pregnant Woman With HIV During the Second Trimester: A Rare Case Report and Review of the Current Literature.Clinical case reports · 2025Article
- Double trouble, managing bilateral inflammatory breast cancer: a case report.Frontiers in oncology · 2025Article
- Reconstructing tumor clonal heterogeneity and evolutionary relationships based on tumor DNA sequencing data.Briefings in bioinformatics · 2024Article
- Survival analysis for patients with metachronous contralateral breast cancer: Insights from a retrospective study.Oncology letters · 2024Article
- B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4NPJ precision oncology · 2024Article
- Patient-derived organoid elucidates the identical clonal origin of bilateral breast cancer with diverse molecular subtypes.Frontiers in oncology · 2024Article
- Article
- A study of clinical and molecular characteristics in bilateral primary breast cancer.Cancer medicine · 2023Article
- A Study on Synchronous Bilateral Breast Cancer Radiotherapy Based on an Accelerator Integrated with Optical Surface Monitoring System.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics and environmental exposures. Little evidence exists regarding immune infiltration and response to treatment in sBBCs. Here we show that the impact of the subtype of breast cancer on levels of tumor infiltrating lymphocytes (TILs, n = 277) and on pathologic complete response (pCR) rates (n = 140) differed according to the concordant or discordant subtype of breast cancer of the contralateral tumor: luminal breast tumors with a discordant contralateral tumor had higher TIL levels and higher pCR rates than those with a concordant contralateral tumor. Tumor sequencing revealed that left and right tumors (n = 20) were independent regarding somatic mutations, copy number alterations and clonal phylogeny, whereas primary tumor and residual disease were closely related both from the somatic mutation and from the transcriptomic point of view. Our study indicates that tumor-intrinsic characteristics may have a role in the association of tumor immunity and pCR and demonstrates that the characteristics of the contralateral tumor are also associated with immune infiltration and response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.